



Contact: CEOcast, Inc.
Dan Schustack
Investor Relations
212-732-4300
DSchustack@ceocast.com

ImmunoCellular Therapeutics Announces Year-End Results

LOS ANGELES, CA – April 1, 2010 – ImmunoCellular Therapeutics, Ltd. (OTC.BB: IMUC) , announced today that it has filed its Annual Report with the Securities and Exchange Commission for the period ended December 31, 2009 on Form 10-K.

"During 2009 the company advanced its leading product candidates ICT-107 and ICT-121 through the release of promising data," said Manish Singh, Ph.D., President and CEO. "We look forward to commencing a Phase II clinical trial for ICT-107 and to enter clinical trials for ICT-121 during the second half of the year."

Some of the fiscal 2009 and recent highlights include:

Financial:

Unqualified Audit Opinion. ImmunoCellular Therapeutics received an unqualified opinion from its independent auditor that it has sufficient capital to fund its clinical development and other operating activities for at least the next twelve months.

Research and license option agreement. The company entered into a research and license option agreement regarding its ICT-69 antibody with Roche Group one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics.

Receipt of \$10 million financial commitment. ImmunoCellular Therapeutics entered into a definitive agreement with Socius Life Sciences Capital Group, LLC. ("Socius"), under which Socius committed to purchase from time to time up to \$10 million of non-convertible Preferred Stock from the Company.

Signed key manufacturing and development agreement for ICT-121. The company entered into an agreement with Formatech, Inc. for the manufacture and development of its cancer stem cell vaccine product candidate, ICT-121, for an upcoming clinical trial. The agreement calls for Formatech to develop a formulation for ICT-121 that allows for long-term stability of the vaccine as well as suitability for intradermal injection.

Scientific:

Promising clinical results from ICT-107 Phase I trials. ICT-107, IMUC's dendritic-cell based cancer vaccine product candidate for the treatment of glioblastoma multiforme (GBM), the most

common and aggressive form of brain cancer, demonstrated the ability to significantly extend the overall survival as well as tumor free survival time compared to the current standard of care.

Identification of novel peptides to broaden applicability of the company's cancer stem cell vaccine candidate, ICT-121. The identification of these peptides enables the use of IMUC's product candidate in patients with many different HLA types. The company also filed a provisional U.S. patent application related to these findings.

Provisional patent application. The company filed a patent application related to its ICT-109 monoclonal antibody product candidate. The application relates to what the company believes is a unique glycosidic composition of an antigen found on the surface of small cell lung cancer, colon cancer and pancreatic cancer, and covers methods for detecting, diagnosing, monitoring, staging, imaging and/or treating the cancers.

Humanization of key antibodies. The company completed humanization of its ICT-37 and ICT-109 antibodies. Humanization is designed to increase acceptance of antibodies by host immune systems. The process was done in collaboration with Antitope, a privately held, UK based biotechnology company.

Added key personnel. Appointed Colonel George Peoples, M.D., Dr. Constantin Ioannides, and Dr. Cohava Gelber to its Scientific Advisory Board.

About ImmunoCellular Therapeutics

IMUC is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The Company recently completed a Phase I trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor associated antigens for glioblastoma. The Company is planning to initiate a multicenter phase II study in the second half of 2010. The Company's "off the shelf" therapeutic vaccine product candidate (ICT-121) targeting cancer stem cells for multiple cancer indications is targeted by IMUC to enter clinical trials for glioblastoma during the second half of 2010. IMUC has entered into a research and license option deal with the Roche Group for one of the Company's monoclonal antibody product candidates for the diagnosis and treatment of ovarian cancer and multiple myeloma, which provides for potential licensing and milestone payments of \$32MM and royalties if the Roche Group exercises its option and commercializes this antibody technology for multiple indications. IMUC is in pre-clinical development of another monoclonal antibody product candidate for the treatment of small cell lung cancer and pancreatic cancer, and is also evaluating its platform technology for monoclonal antibody discovery to target cancer stem cells. To learn more about IMUC, please visit www.imuc.com.

Forward-Looking Statements

This press release contains certain forward-looking statements that are subject to a number of risks and uncertainties, including without limitation, the risks associated with the potential inability to obtain licenses from third parties that will be needed to commercialize ICT-107 in many major commercial territories; the potential inability to secure a partner to fund development and marketing of ICT-107; the risk that future trials of ICT-107, if any, do not confirm the safety and efficacy data generated in the Phase I trial; the need to satisfy performance milestones to maintain the vaccine

technology licenses with Cedars-Sinai; the risks associated with obtaining a patent that provides commercially significant protection for ICT-107; the risk of encountering substantial delays in completing or being unable to successfully complete the pre-clinical testing necessary before initiating clinical testing of ICT-121; and the need for substantial additional capital to fund development of product candidates beyond their initial clinical or pre-clinical stages and to continue IMUC's operations. Additional risks and uncertainties are described in IMUC's most recently filed SEC documents, such as its most recent annual report on Form 10-K, all quarterly reports on Form 10-Q and any current reports on Form 8-K. IMUC undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

###